Objective: A case of acute myocarditis associated with the commencement of clozapine is described, highlighting the onset, course and possible contributing factors. There is an urgent need to raise awareness about this potentially fatal complication of clozapine use.
Results: A 20-year-old male with schizophrenia developed a sudden onset of myocarditis after commencement of clozapine. The patient recovered with intensive medical support. The symptoms occurred around 2 weeks after starting clozapine in an inpatient setting. Possible contributing factors may have been concomitant antidepressant use and unaccustomed physical activity.
Conclusions: Myocarditis is an increasingly recognized complication associated with the use of clozapine. It can be fatal if not recognized and treated early. Considering that clozapine remains the gold standard in treatment of resistant psychosis, there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients. There are also implications for recommendations and regulations regarding the use of clozapine.
KaneJHonigfeldGSingerJMeltzerH. Clozapine for the treatment-resistant schizophrenic; a double blind comparison with chlorpromazine. Archives in General Psychiatry1988; 45: 789–796.
2.
WalkerAMLanzaLLArellanoFRothmanKJ. Mortality in current and former users of Clozapine. Epidemiology1997; 8: 671–677.
3.
MeltzerHY. Suicide and schizophrenia: clozapine and the InterSePT study. International Clozaril/Leponex Suicide Prevention Trial. Journal of Clinical Psychiatry1999; 60(Suppl 12)47–50.
4.
HonigfeldG. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatric Services1996; 47: 52–56.
5.
ReindersJParsonageWLangeDPotterJMPleverS. Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Australian and New Zealand Journal of Psychiatry2004; 38: 915–922.
6.
CoulterDMBateAMeyboomRHBLindquistMEdwardsIR. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. British Mecical Journal2001; 322: 1207–1209.
7.
HaggSSpigsetOBateASoderstromTG. Myocarditis related to clozapine treatment. Journal of Clinical Psychopharmacology2001; 21: 382–388.
8.
GrenadeLLGrahamDTrontellA. Myocarditis and cardiomyopathy associated with clozapine use in the United States. New England Journal of Medicine2001; 345: 224.
9.
KilianJGKerrKLawrenceCCelermajerDS. Myocarditis and cardiomyopathy associated with clozapine. Lancet1999; 354: 1841–1845.
10.
TirupatiS. Clozapine and heart in the Hunter region. Australian and New Zealand Journal of Psychiatry2006; 40: 97.
11.
KaySEDoeryJShollD. Clozapine associated pericarditis and elevated troponin I. Australian and New Zealand Journal of Psychiatry2002; 36: 143–144.
12.
MurkoAClarkeSBlackDW. Clozapine and pericarditis with pericardial effusion. American Journal of Psychiatry2002; 159: 494.
13.
BandelowBDegnerDKreuschURutherE. Myocarditis under therapy with clozapine. Schizophrenia Research1995; 17: 293–294.
14.
WooltortonE. Antipsychotic clozapine (Clozaril); myocarditis and cardiovascular toxicity. Canadian Medical Association Journal2002; 166: 1185–1186.
15.
BurkeAPSaengerJMullickFVirmaniR. Hypersensitivity myocarditis. Archives of Pathological and Laboratory Medicine1991; 115: 764–769.
16.
VarmaSAchanK. Dysrhythmia associated with clozapine. Australian and New Zealand Journal of Psychiatry1999; 33: 118–119.
17.
KorenWKreisYDuchowicznyK. Lactic acidosis and fatal myocardial failure due to clozapine. Annals of Pharmacotherapy1997; 31: 168–170.
18.
LapierreYDGhadirianASt. LaurentJChaudhryRP. Clozapine in acute schizophrenia – efficacy and toxicity. Current Therapeutic Research1980; 27: 391–400.
